These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20872033)

  • 1. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study.
    Mattioli F; Stampatori C; Capra R
    Neurol Sci; 2011 Feb; 32(1):83-8. PubMed ID: 20872033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
    Weinstock-Guttman B; Galetta SL; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; O'Connor PW; Phillips JT; Polman C; Stuart WH; Lynn F; Hotermans C
    J Neurol; 2012 May; 259(5):898-905. PubMed ID: 22008873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
    Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
    CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
    Belachew S; Phan-Ba R; Bartholomé E; Delvaux V; Hansen I; Calay P; Hafsi KE; Moonen G; Tshibanda L; Vokaer M
    Eur J Neurol; 2011 Feb; 18(2):240-245. PubMed ID: 20561044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.
    Edgar C; Jongen PJ; Sanders E; Sindic C; Goffette S; Dupuis M; Jacquerye P; Guillaume D; Reznik R; Wesnes K
    BMC Neurol; 2011 Jun; 11():68. PubMed ID: 21649910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.
    López-Góngora M; Querol L; Escartín A
    BMC Neurol; 2015 Mar; 15():40. PubMed ID: 25886168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
    Mattioli F; Stampatori C; Bellomi F; Scarpazza C; Capra R
    PLoS One; 2015; 10(7):e0131803. PubMed ID: 26148120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR lesion load and cognitive function in patients with relapsing-remitting multiple sclerosis.
    Fulton JC; Grossman RI; Udupa J; Mannon LJ; Grossman M; Wei L; Polansky M; Kolson DL
    AJNR Am J Neuroradiol; 1999; 20(10):1951-5. PubMed ID: 10588124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
    Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
    Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis.
    Calabrese M; Rinaldi F; Grossi P; Mattisi I; Bernardi V; Favaretto A; Perini P; Gallo P
    Mult Scler; 2010 Oct; 16(10):1220-8. PubMed ID: 20670981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
    Sundgren M; Piehl F; Wahlin Å; Brismar T
    Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
    Rorsman I; Petersen C; Nilsson PC
    Acta Neurol Scand; 2018 Jan; 137(1):117-124. PubMed ID: 28901547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.
    Portaccio E; Stromillo ML; Goretti B; Hakiki B; Giorgio A; Rossi F; De Leucio A; De Stefano N; Amato MP
    Eur J Neurol; 2013 Jun; 20(6):986-90. PubMed ID: 23057658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of natalizumab for relapsing multiple sclerosis.
    Miller DH; Khan OA; Sheremata WA; Blumhardt LD; Rice GP; Libonati MA; Willmer-Hulme AJ; Dalton CM; Miszkiel KA; O'Connor PW;
    N Engl J Med; 2003 Jan; 348(1):15-23. PubMed ID: 12510038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.